John W. Gillard

4.7k total citations · 2 hit papers
49 papers, 3.4k citations indexed

About

John W. Gillard is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, John W. Gillard has authored 49 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 14 papers in Organic Chemistry and 8 papers in Pharmacology. Recurrent topics in John W. Gillard's work include Cell death mechanisms and regulation (8 papers), Asthma and respiratory diseases (6 papers) and Bioactive Compounds and Antitumor Agents (5 papers). John W. Gillard is often cited by papers focused on Cell death mechanisms and regulation (8 papers), Asthma and respiratory diseases (6 papers) and Bioactive Compounds and Antitumor Agents (5 papers). John W. Gillard collaborates with scholars based in Canada, United States and Australia. John W. Gillard's co-authors include Philip J. Vickers, Douglas K. Miller, Jon P. Durkin, Jilly F. Evans, Stephen J. Morris, Richard A. F. Dixon, Kathleen M. Dickson, Snezana Milutinovic, Philip A. Barker and James B. Jaquith and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Molecular Cell.

In The Last Decade

John W. Gillard

48 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

cIAP1 and cIAP2 Facilitate Cancer Cell Survival by Functioning as E3 Ligases that Promote RIP1 Ubiquitination

2008 874 citations Mathieu J.M. Bertrand, Snezana Milutinovic et al. Molecular Cell profile →
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

1990 622 citations Richard A. F. Dixon, Philip J. Vickers et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John W. Gillard Canada	26	1.7k	914	713	483	454	49	3.4k
Robert J. Bonney United States	29	1.1k 0.6×	621 0.7×	477 0.7×	745 1.5×	242 0.5×	56	3.2k
Hans‐Erik Claesson Sweden	34	1.2k 0.7×	1.0k 1.1×	1.0k 1.4×	726 1.5×	223 0.5×	109	3.6k
Karen L. MacNaul United States	28	1.6k 0.9×	319 0.3×	681 1.0×	303 0.6×	247 0.5×	36	3.3k
Martha K. Cathcart United States	39	1.4k 0.8×	2.1k 2.3×	589 0.8×	233 0.5×	234 0.5×	80	4.6k
John L. Humes United States	29	1.1k 0.6×	776 0.8×	567 0.8×	1.2k 2.6×	302 0.7×	63	3.7k
Nathalie Andrieu‐Abadie France	36	3.1k 1.8×	809 0.9×	710 1.0×	165 0.3×	332 0.7×	85	4.5k
Quansheng Zhou China	37	2.3k 1.3×	871 1.0×	433 0.6×	282 0.6×	200 0.4×	89	3.7k
Philip J. Vickers Canada	24	1.3k 0.8×	729 0.8×	942 1.3×	1.5k 3.0×	364 0.8×	36	3.8k
Roy J. Soberman United States	38	1.3k 0.7×	1.0k 1.1×	1.1k 1.6×	490 1.0×	121 0.3×	77	3.6k
Larry W. Daniel United States	31	2.3k 1.3×	515 0.6×	476 0.7×	213 0.4×	191 0.4×	68	3.2k

Countries citing papers authored by John W. Gillard

Since Specialization

Citations

This map shows the geographic impact of John W. Gillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. Gillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. Gillard more than expected).

Fields of papers citing papers by John W. Gillard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. Gillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. Gillard. The network helps show where John W. Gillard may publish in the future.

Co-authorship network of co-authors of John W. Gillard

This figure shows the co-authorship network connecting the top 25 collaborators of John W. Gillard. A scholar is included among the top collaborators of John W. Gillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W. Gillard. John W. Gillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zimpelmann, Joseph, et al.. (2023). Effects of Two Soluble ACE2-Fc Variants on Blood Pressure and Albuminuria in Hypertensive Mice: Research Letter. Canadian Journal of Kidney Health and Disease. 10. 1035162346–1035162346.

Le, Phuong Uyen, et al.. (2016). Inhibition of carbonic anhydrase IX in glioblastoma multiforme. European Journal of Pharmaceutics and Biopharmaceutics. 109. 81–92. 30 indexed citations

Bertrand, Mathieu J.M., Snezana Milutinovic, Kathleen M. Dickson, et al.. (2008). cIAP1 and cIAP2 Facilitate Cancer Cell Survival by Functioning as E3 Ligases that Promote RIP1 Ubiquitination. Molecular Cell. 30(6). 689–700. 874 indexed citations breakdown →

Zehntner, Simone P., Lyne Bourbonnière, Craig S. Moore, et al.. (2007). X-linked Inhibitor of Apoptosis Regulates T Cell Effector Function. The Journal of Immunology. 179(11). 7553–7560. 20 indexed citations

LaCasse, Eric C., Stephen Morris, Tim Ward, et al.. (2006). AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients. Cancer Research. 66. 1142–1142. 3 indexed citations

Salehi, Amir H., Stephen J. Morris, Kathleen M. Dickson, et al.. (2006). AEG3482 Is an Antiapoptotic Compound that Inhibits Jun Kinase Activity and Cell Death through Induced Expression of Heat Shock Protein 70. Chemistry & Biology. 13(2). 213–223. 43 indexed citations

LaCasse, Eric C., Ekambar R. Kandimalla, P.D. Winocour, et al.. (2005). Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM®640. Annals of the New York Academy of Sciences. 1058(1). 215–234. 52 indexed citations

Ilan, Ehud, Shlomo Dagan, Ofer Nussbaum, et al.. (1999). The Hepatitis B Virus-Trimera Mouse: A Model for Human Hbv Infection and Evaluation of Anti–Hbv Therapeutic Agents. Hepatology. 29(2). 553–562. 81 indexed citations

Llinàs‐Brunet, Montse, Dale R. Cameron, Jean‐Marie Ferland, et al.. (1999). Phosphotyrosine-Containing Dipeptides as High-Affinity Ligands for the p56^lck SH2 Domain. Journal of Medicinal Chemistry. 42(4). 722–729. 10 indexed citations

10.

Mansour, Tarek S., Haolun Jin, Wei Wang, et al.. (1995). Structure-Activity Relationships Among a New Class of Antiviral Heterosubstituted 2′,3′-Dideoxynucleoside Analogues. Nucleosides and Nucleotides. 14(3-5). 627–635. 18 indexed citations

11.

Ducharme, Yves, Christine Brideau, Daniel Dubé, et al.. (1994). Naphthalenic Lignan Lactones as Selective, Nonredox 5-Lipoxygenase Inhibitors. Synthesis and Biological Activity of (Methoxyalkyl)thiazole and Methoxytetrahydropyran Hybrids. Journal of Medicinal Chemistry. 37(4). 512–518. 31 indexed citations

12.

Young, Robert N., John W. Gillard, John H. Hutchinson, Serge Léger, & Peppi Prasit. (1993). Discovery of inhibitors of the 5-lipoxygenase activating protein (flap).. PubMed. 6(1-3). 233–8. 7 indexed citations

13.

Mancini, Joseph A., Petpiboon Prasit, Marc G. Coppolino, et al.. (1992). 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.. Molecular Pharmacology. 41(2). 267–272. 31 indexed citations

14.

Miller, Douglas K., John W. Gillard, Philip J. Vickers, et al.. (1990). Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 343(6255). 278–281. 382 indexed citations

15.

Mais, Dale E., Christiane Yoakim, Yvan Guindon, et al.. (1989). Photoaffinity labelling of the human platelet thromboxane A2/prostaglandin H2 receptor. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1012(2). 184–190. 26 indexed citations

16.

Mayeux, Philip R., Howard E. Morton, John W. Gillard, et al.. (1988). The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets. Biochemical and Biophysical Research Communications. 157(2). 733–739. 46 indexed citations

17.

Gillard, John W. & P M Bélanger. (1987). Metabolic synthesis of arylacetic acid antiinflammatory drugs from arylhexenoic acids. 2. Indomethacin. Journal of Medicinal Chemistry. 30(11). 2051–2058. 7 indexed citations

18.

Commereuc, D., et al.. (1984). Dimerize ethylene to butene-1. Hydrocarbon Process. 63(11). 118–120. 9 indexed citations

19.

Gillard, John W., et al.. (1981). Biogenesis of Proteaceous Alkaloids. Planta Medica. 41(4). 379–385. 4 indexed citations

20.

Bick, I. R. C., JB Bremner, & John W. Gillard. (1973). The synthesis of bellendine. Tetrahedron Letters. 14(51). 5099–5100. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact